Apr 16, 2020
The Oligonucleotide Synthesis, Modification and Purification Services Market is Expected to Grow at an Annualized Rate of over 10%, Claims Roots Analysis
Nov 14, 2019
Poised for Significant Growth and Profitability, BioMarin Shares Company Highlights During R&D Day on November 14th in New York
Nov 12, 2019
BioMarin to Participate in Jefferies London Healthcare Conference on November 21, 2019
Nov 06, 2019
BioMarin to Highlight Innovative Development Pipeline at R&D Day on November 14th
Oct 23, 2019
BioMarin Announces Third Quarter 2019 Financial Results
Oct 09, 2019
BioMarin to Host Third Quarter 2019 Financial Results Conference Call and Webcast on Wednesday, October 23 at 4:30pm ET
Oct 07, 2019
BioMarin Promotes Lon Cardon, Ph.D. to Chief Scientific Strategy Officer
Oct 01, 2019
BioMarin to Participate in Jefferies Gene Therapy/Editing Summit on October 8, 2019 in New York
Sep 26, 2019
BioMarin, Pioneer in Phenylketonuria (PKU) Therapies, Submits Clinical Trial Application (CTA) in U.K. for Investigational Gene Therapy for PKU
Sep 09, 2019
BioMarin to Participate in Morgan Stanley 17th Annual Global Healthcare Conference on September 10, 2019 in New York
Aug 28, 2019
BioMarin to Participate in Morgan Stanley 17th Annual Global Healthcare Conference on September 10, 2019 in New York
Jul 16, 2019
BioMarin to Host Second Quarter 2019 Financial Results Conference Call and Webcast on Thursday, August 1 at 4:30pm ET
Jul 09, 2019
BioMarin Appoints Pharmaceutical Veteran and Former J & J Executive, Liz McKee Anderson, to Board of Directors
Jul 08, 2019
BioMarin Plans Regulatory Submissions for Marketing Authorization of Valoctocogene Roxaparvovec to Treat Severe Hemophilia A in 4Q 2019 in both U.S. and Europe
Jun 26, 2019
BioMarin Announces Acceptance of Late Breaking Abstract at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress in Melbourne, Australia from July 6-10, 2019
Jun 21, 2019
BioMarin Earns Milestone Payments from Pfizer for TALZENNA® (talazoparib) for Metastatic Breast Cancer Patients with an Inherited BRCA Mutation
Jun 05, 2019
BioMarin to Participate in Goldman Sachs 40th Annual Global Healthcare Conference on Tuesday, June 11 in Rancho Palos Verdes, CA
Jun 04, 2019
BioMarin Announces Approval of Vimizim® (elosulfase alfa) in China for Treatment of Morquio A Syndrome
May 28, 2019
BioMarin Announces that Phase 3 Cohort of Valoctocogene Roxaparvovec, Gene Therapy Study in Severe Hemophilia A Met Pre-Specified Criteria for Regulatory Submissions in the U.S. and Europe
May 27, 2019
BioMarin to Host Conference Call Tuesday, May 28, 2019 to Provide a Valoctocogene Roxaparvovec Phase 2 and Phase 3 Update